---
pmid: '36442525'
title: ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer progression.
authors:
- Fang X
- Lee YH
- Jang JH
- Kim SJ
- Kim SH
- Kim DH
- Na HK
- Kim KO
- Baek JH
- Surh YJ
journal: Life Sci
year: '2023'
full_text_available: false
doi: 10.1016/j.lfs.2022.121217
---

# ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer progression.
**Authors:** Fang X, Lee YH, Jang JH, Kim SJ, Kim SH, Kim DH, Na HK, Kim KO, Baek JH, Surh YJ
**Journal:** Life Sci (2023)
**DOI:** [10.1016/j.lfs.2022.121217](https://doi.org/10.1016/j.lfs.2022.121217)

## Abstract

1. Life Sci. 2023 Jan 15;313:121217. doi: 10.1016/j.lfs.2022.121217. Epub 2022
Nov  25.

ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer 
progression.

Fang X(1), Lee YH(1), Jang JH(1), Kim SJ(2), Kim SH(1), Kim DH(3), Na HK(4), Kim 
KO(5), Baek JH(6), Surh YJ(7).

Author information:
(1)College of Pharmacy, Seoul National University, Seoul, South Korea.
(2)Department of Molecular Medicine and Biopharmaceutical Science, Graduate 
School of Convergence Science and Technology, Seoul National University, Seoul, 
South Korea.
(3)Department of Chemistry, College of Convergence and Integrated Science, 
Kyonggi University, Suwon, Gyeonggi-do, South Korea.
(4)Department of Food Science and Biotechnology, College of Knowledge-Based 
Services Engineering, Sungshin Women's University, Seoul, South Korea.
(5)Gachon Medical Research Institute, Gil Medical Center, Gachon University, 
Incheon, South Korea.
(6)Division of Colon and Rectal Surgery, Department of Surgery, Gil Medical 
Center, Gachon University College of Medicine, Incheon, South Korea.
(7)College of Pharmacy, Seoul National University, Seoul, South Korea; Cancer 
Research Institute, Seoul National University, Seoul, South Korea. Electronic 
address: surh@snu.ac.kr.

AIMS: Aberrant overactivation/overexpression of NRF2 is implicated as a driving 
event in tumor progression, which has been attributed to its mutation or 
inactivation of the inhibitory protein, KEAP1. However, alternative mechanisms 
responsible for sustained activation of NRF2 are less understood.
MAIN METHODS: Human colon cancer cell lines and tissues obtained from colorectal 
cancer (CRC) patients were used. To examine the expression levels of ARD1 and 
NRF2, Western blot and immunofluorescence analyses were performed. To 
investigate the potential relevance of NRF2 and ARD1 to human CRC, NRF2 and ARD1 
were individually silenced in human colon cancer cells (HCT-116) by transfection 
with their specific small interfering RNA (siRNA). To determine the functional 
role of ARD1 in NRF2 regulation, in situ proximate ligation, 
co-immunoprecipitation, nano-LC-ESI MS/MS, and in vitro acetylation assays were 
performed.
KEY FINDINGS: ARD1 knockdown in human colon cancer cell lines significantly 
reduced the protein levels of NRF2 without affecting its mRNA expression; 
however, silencing of NRF2 did not alter ARD1 protein expression. In addition, 
these two proteins were co-localized and physically interacted with each other 
both in human colon cancer cells (HCT-116) and human colon tumor tissues. 
Mechanistically, ARD1 overexpression increased the acetylation levels of NRF2. 
Moreover, an in vitro acetylation assay and mass spectrometric analysis 
demonstrated that ARD1 could directly acetylate NRF2. Ectopic expression of 
mutant forms of ARD1 with defective acetyltransferase activity reduced the 
stability of NRF2.
SIGNIFICANCE: In conclusion, ARD1 may potentiate the oncogenic function of NRF2 
in human colon cancer by stabilizing this transcription factor.

Copyright Â© 2022 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.lfs.2022.121217
PMID: 36442525 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of competing interest The authors 
declare no competing financial interests.
